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Stroke is the third leading cause of death and a major 
cause of disability in adults. In Poland, up to 80,000 peo-
ple suffer from stroke each year; 25% die within 90 days, 
and those who survive need support in everyday life. 
Acute stroke treatment with IV rt-PA, routinely avail-
able since the 1990s, can be utilised in only a small per-
centage of stroke victims. IV rt-PA gives a 30% increase in 
the number of patients who recover completely. The low 
percentage of patients who can be treated with IV rt-PA 
is due to its narrow therapeutic window (4.5 h). During 
that timeframe, not only must a  detailed interview be 
conducted and a neurological examination be performed, 
but also brain neuroimaging and several blood tests 
must be obtained. To complete all of these procedures 
in such a short timeframe requires perfect organisation 
and the close collaboration of all parties involved in the 
treatment process. In Poland, treatment with IV rt-PA is 
performed in stroke units that are typically divisions of 
neurology departments.
In the last few years, leading European and American 
stroke centres have introduced endovascular treatment 
– mechanical thrombectomy and, to a  much lesser ex-
tent, pharmacological treatment by intra-arterial (IA) rt-
PA. Pharmacological IA treatment can only be performed 
following consultation with an ethics committee, since 
the efficacy of these interventional treatments has not 
been confirmed in large clinical trials. It should be noted 
that mechanical thrombectomy can be used up to 8 h 
following onset of symptoms for strokes located in the 
anterior circulation, and in some specific cases even up 
to 24 h later. This wider treatment window allows us to 
employ this interventional treatment for many more vic-
tims of acute stroke. Information concerning the current 
indication for endovascular treatment of acute stroke is 
available in European (European Stroke Organisation) 
and American (American Heart Association/American 
Stroke Association) guidelines. 
The first device for mechanical thrombectomy in 
acute stroke, MERCI (Concentric Medical), was approved 
by the FDA in the US 10 years ago. The second device, 
Penumbra (Penumbra, Alameda, CA, USA), was approved 
several years later. Although both devices increased sig-
nificantly the percentage of brain vessels that were re-ca-
nalised, the percentage of patients who recovered com-
pletely was still less than 25%. 
Stent retrievers, a new generation of devices for me-
chanical thrombectomy, have recently been introduced 
and are more efficacious and safer than the older devic-
es. In 2012 the FDA and the EMA registered two stent 
retrievers: SOLITAIRE (Solitaire.ev3.Irvine, CA, USA) and 
TREVO (Trevo; Stryker, Kalamazoo, MI, USA). Their sig-
nificant advantage as compared with MERCI was shown 
in two important clinical studies: the Swift (SOLITAIRE) 
trial and the Trevo 2 trial (TREVO), published in “Lancet” 
in 2012 [1, 2]. Both studies showed a very high percent-
age of recanalisation: 83% (Solitaire) and 89% (Trevo). 
Fifty-eight percent of patients treated with Solitaire and 
55% of those treated with Trevo recovered completely. 
Most importantly, the percentage of patients who devel-
oped brain haemorrhages due to treatment with these 
devices was low: 2% in patients treated with Solitaire and 
6.8% in patients treated with Trevo. The efficacy of both 
retrievers was later confirmed in national registries. An 
increasing number of stent retrievers with new modifica-
tions is now available, including CATCH+ (BALT), pREset 
(Phenox), ASPERIO (Acandis), and Revive SE (Codman).
In 2013, optimism related to endovascular treatment 
of acute stroke was considerably tempered, since the 
results of three negative clinical studies that compared 
mechanical thrombectomy with standardised treatment 
were published in NEJM (“New England Medical Journal”). 
The first study, “Endovascular Therapy after intravenous 
t-PA versus t-PA alone for stroke (IMSIII)” [3], included 
656 acute stroke patients. Two hundred and twenty-two 
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patients were treated with IV rt-PA alone within 3 h af-
ter stroke onset, while the remaining patients received 
endovascular treatment in addition to IV-rt-PA. The sec-
ond study, “A Trial of Imaging selection and endovascular 
treatment for ischaemic stroke” [4], was performed in 
118 patients recruited within 8 h after the onset of 
large-vessel anterior-circulation strokes. Seventy patients 
received mechanical thrombectomy while 57 patients 
received standard treatment. The third study, “Endovas-
cular Treatment of acute ischaemic stroke: SYNTHESIS 
EXPANSION” [5], included 362 patients. Treatment was 
initiated within 4.5 h following stroke onset: 50% re-
ceived endovascular treatment (IA rt-PA and/or mechan-
ical thrombectomy), and 50% received IV rt-PA only. The 
publication of these papers precipitated a  lively discus-
sion in the literature, including the NEJM, and resulted 
in several objections to the study protocols, including 
the slow recruitment of patients, the lack of information 
concerning anaesthesia, the lack of routine brain vessel 
imaging that would have localised the thrombus prior to 
the procedure, and most importantly, the use of primarily 
older devices for mechanical thrombectomy. 
Although these three studies did not show an advan-
tage for endovascular treatment over standard therapy 
in acute stroke, detailed analysis of all clinical studies 
and registries published so far, as well as several per-
sonal communications and comments published in lead-
ing journals, allows one to conclude the following: 1) the 
new generation of devices for mechanical thrombectomy 
(stent retrievers) are more efficacious than older devices 
such as MERCI (better recanalisation, higher percentage 
of patients who recovered completely), and these devic-
es are now the most commonly used ones for mechanical 
thrombectomy in acute stroke; 2) endovascular treatment 
is efficacious only in a small percentage of acute stroke pa-
tients, i.e. patients with more severe stroke due to occlu-
sion of M1 or M2 of the middle cerebral artery or the basi-
lar or vertebral arteries (IV rt-PA is much less efficacious in 
these cases); and 3) before deciding to proceed with endo-
vascular treatment, patients should have imaging of brain 
vessels performed to localise the thrombus and to exclude 
arterio-venous malformations or carotid artery stenosis.
At present, several clinical trials to evaluate the sig-
nificance of endovascular treatment as compared with 
standardised therapy are in progress (http://www.sni-
sonline.org/stroketrials). Unfortunately, recruitment for 
these trials is proceeding slowly and the results are ex-
pected no earlier than within the next few years. This is 
because several new devices for mechanical thrombec-
tomy in acute stroke have already been approved by the 
FDA and the EMA, and patients prefer treatment with 
mechanical thrombectomy in a  clinical setting rather 
than by participating in clinical trials. 
In everyday practice, many countries require that all 
stroke patients treated with mechanical thrombectomy 
be entered into standard registries, for example the SITS 
Thrombectomy Registry, which includes patients from 
several European countries. This approach is very helpful 
in evaluating the efficacy and complications of these rare 
procedures. 
In the USA, endovascular treatment in acute stroke 
is performed in highly specialised Comprehensive Stroke 
Centres. In 2005, the Brain Attack Coalition published the 
requirements for such centres [6]. According to this doc-
ument, Comprehensive Stroke Centres should employ 
several high quality experts in stroke and subarachnoid 
haemorrhage, including neurologists, radiologists, vas-
cular surgeons, neurosurgeons, and anaesthesiologists. 
Each Comprehensive Stroke Centre must have access to 
MRI/MRA, CTA, DSA, and TCD and round-the-clock (24/7) 
access to interventional treatment.
Epidemiological data from the USA indicate that no 
more than 2% of stroke victims undergo endovascular treat-
ment (compared with 70% of patients with acute coronary 
disease who undergo endovascular treatment at present).
In the USA, there is a need for approximately 200 Com-
prehensive Stroke Centres and 600–800 interventional ra-
diologists (three specialists for each centre). In Poland, the 
estimated number of patients who potentially fulfil cri-
teria for endovascular treatment varies from 1500–2000. 
The estimated number of Comprehensive Stroke Centres 
that are required varies from 15–20. 
In Poland, the first centre that fulfils the criteria for 
a Comprehensive Stroke Centre and has introduced round-
the-clock access for endovascular acute stroke treatment 
is the Centre for Interventional Therapy of Acute Stroke at 
the University Hospital in Krakow. So far, 40 acute stroke 
patients were treated with mechanical thrombectomy 
and all are followed according to the protocol approved by 
the local ethics committee. The experience of the Krakow 
Comprehensive Stroke Centre may help to establish other 
Comprehensive Stroke Centres in Poland.
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